ArticleClinical interventions in aging2023
Comparison of Diagnostic Value of the SARC-F and Its Four Modified Versions in Polish Community-Dwelling Older Adults.
Article in Clinical interventions in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluating the Discriminative Performance of SARC-F and SARC-CalF in Identifying Functional Impairment in Community-Dwelling Older Adults.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2026Observational
- Screening and diagnosis tools for sarcopenia: an overview of systematic reviews.Systematic reviews · 2026Review
- Translation, Cross-Cultural Adaptation, and Validation of the Croatian Version of the SARC-F Questionnaire for Assessing Sarcopenia in Older Adults.Healthcare (Basel, Switzerland) · 2026Article
- Calf circumference as a simple tool versus chest-CT derived skeletal muscle index in assessing osteosarcopenia and one-year outcomes in osteoporotic vertebral fractures.Aging clinical and experimental research · 2026Article
- Diagnostic accuracy of sarcopenia screening tools in low-income older adults in Amazonas, Brazil.Aging clinical and experimental research · 2025Article
- Sarcopenia: Current Insights into Molecular Mechanisms, Diagnostics, and Emerging Interventional Approaches.International journal of molecular sciences · 2025Review
- Fatigue and Vitamin D Status in Frail Elderly with and without Cancer, and Healthy Controls of Different Ages: Results from the IMAGE Study.Gerontology · 2025Observational
- Prevalence and Diagnostic Strategies for Sarcopenia in Menopausal and Non-Menopausal Women: A Cross-Sectional Comparative Study.International journal of women's health · 2025Article
- Evaluating SARC-F, SARC-CalF, and calf circumference as diagnostic tools for sarcopenia in Thai older adults: results from a nationwide study.BMC geriatrics · 2024Observational
- Development and validation of a screening tool for sarcopenia in Chinese nursing home residents.iScience · 2024Article
- Exploring the role of body mass index-adjusted calf circumference within the SARC-CalF screening tool among older patients with cancer.The journal of nutrition, health & aging · 2024Article
- Comparison of six screening methods for sarcopenia among rural community-dwelling older adults: a diagnostic accuracy study.European geriatric medicine · 2024Article
- Diagnostic Criteria and Measurement Techniques of Sarcopenia: A Critical Evaluation of the Up-to-Date Evidence.Nutrients · 2024Review
- Construction of frailty and risk prediction models in maintenance hemodialysis patients: a cross-sectional study.Frontiers in medicine · 2024Article
- Diagnostic performance of SARC-F and SARC-CalF in screening for sarcopenia in older adults in Northern Brazil.Scientific reports · 2023Article
- Development and validation of a Sarcopenia Geriatric Scale (SARCO-GS): a new short scale for the screening of sarcopenia.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sarcopenia is associated with adverse outcomes in elderly persons, including functional disability, falls, and even death. Therefore, older adults should be routinely screened for sarcopenia. Due to the unsatisfactory sensitivity of the SARC-F questionnaire, four modified versions have been elaborated: SARC-CalF, SARC-F+EBM, SARC-F+AC, and SARC-CalF+AC. The diagnostic performance of the four modifications of SARC-F has yet to be compared. Materials and Methods: We performed the sensitivity/specificity analysis and compared the overall diagnostic accuracy of the five questionnaires in 260 community-dwelling volunteers aged ≥ 60 yrs from Poland. The study was performed against three reference standards: the European Working Group on Sarcopenia in Older People (EWGSOP1), EWGSOP2, and modified EWGSOP2 criteria. Results: The prevalence of sarcopenia based on these criteria was 20.8%, 11.2%, and 17.3%, respectively. Concerning the three reference standards, the sensitivity of SARC-F, SARC-CalF, SARC-F+EBM, SARC-F+AC, and SARC-CalF+AC ranged from 31.5-44.8%, 57.4-65.5%, 48.1-62.1%, 71.4-79.2% and 71.4-79.2%, respectively. The specificity ranged from 86.6-87.4%, 86.1-90.3%, 82.3-84.0%, 69.4-78.2%, and 72.1-79.7%, respectively. The AUCs of SARC-F, SARC-CalF, SARC-F+EBM, SARC-F+AC, and SARC-CalF+AC ranged from 0.643-0.700, 0.757-0.792, 0.740-0.775, 0.767-0.812 and 0.771-0.852, respectively. Conclusion: The SARC-F questionnaire has low diagnostic accuracy, which limits its usefulness as a sarcopenia screening tool. Incorporating two simple anthropometric measurements, ie, arm and calf circumference, notably improves the diagnostic performance of SARC-F. Based on our results, SARC-CalF+AC seems to be the best screening tool for sarcopenia screening in community-dwelling older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.